DrugPatentWatch Database Preview
Heron Theraps Inc Company Profile
What is the competitive landscape for HERON THERAPS INC, and when can generic versions of HERON THERAPS INC drugs launch?
HERON THERAPS INC has two approved drugs.
There are twelve US patents protecting HERON THERAPS INC drugs.
There are twenty-two patent family members on HERON THERAPS INC drugs in ten countries and seven supplementary protection certificates in four countries.
Summary for Heron Theraps Inc
| International Patents: | 22 |
| US Patents: | 12 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Heron Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 6,613,355 | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 10,357,570 | Start Trial | Start Trial | ||||
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 8,715,710 | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 9,974,794 | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 9,974,793 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Heron Theraps Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2015034182 | Start Trial |
| South Korea | 20070083851 | Start Trial |
| Hong Kong | 1213477 | Start Trial |
| European Patent Office | 3424492 | Start Trial |
| Japan | 2017533183 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Heron Theraps Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0734381 | 04C0010 | France | Start Trial | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
| 0734381 | PA2004002 | Lithuania | Start Trial | PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111 |
| 0734381 | 3/2004 | Austria | Start Trial | PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111 |
| 0748320 | 08C0019 | France | Start Trial | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| 0734381 | PA2004002,C0734381 | Lithuania | Start Trial | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
